Amgen announces positive results from AMG 145 Phase 2 RUTHERFORD study

November 5, 2012

Amgen announced that treatment with AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a reduction in low density lipoprotein cholesterol, or LDL-C, or "bad" cholesterol, by up to 56% in patients with heterozygous familial hypercholesterolemia, or HeFH, in the Phase 2 RUTHERFORD study. AMG 145 is an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove LDL-C from the blood. The study was published in Circulation and simultaneously presented in a late-breaking clinical trial session at the American Heart Association Scientific Sessions 2012.